The Spine Biologics market is on the brink of significant growth, with projections indicating it will surpass USD 3.5 billion by 2033, showcasing a steady CAGR of 4.2% between 2023 and 2031.
Several key factors are driving investor interest in this sector. The demographic shift toward an aging population, combined with a growing prevalence of spine abnormalities, is creating a rising demand for innovative solutions within Spine Biologics.
Additionally, the development and introduction of advanced stem cell therapies are playing a pivotal role in bolstering this market. Stem cell research has demonstrated its potential for promoting tissue regeneration and enhancing patient outcomes in spinal fusion surgeries.
Biologic materials are also making significant strides, offering promising alternatives to spinal treatments. These biologics come with advantages such as faster recovery times, reduced postoperative discomfort, and the ability to stimulate cellular growth, making them highly sought-after in the global Spine Biologics market.
In this report, we will delve deeper into the growing sector, exploring some of the emerging players.
HippoFi, Inc. (OTC:ORHB) is a dynamic player in the healthcare sector, driving innovations and proprietary technologies across various markets, including biotech, fintech, and artificial intelligence (AI). Their approach is multifaceted, with a focus on Regenerative Therapeutics, Digital Payments, and AI. What sets HippoFi apart is its extensive sales channel network, which enables them to deliver cutting-edge solutions while also achieving first-to-market status.
PUR Biologics, a wholly-owned subsidiary of HippoFi, Inc., specializes in biologic products designed to support healthcare professionals, particularly surgeons and hospitals. PuR Biologics offers a wide range of products, including sophisticated allografts, demineralized extracellular matrices (d-ECM), artificial bone-forming agents, tissues derived from cells, and the exciting field of regenerative stem cell and growth factor-driven therapeutics. Their mission is clear: to enhance patient care by providing the best possible tools and solutions.
On September 6, 2023, HippoFi, Inc. made a groundbreaking announcement that has the healthcare industry buzzing with excitement. They proudly revealed a strategic partnership with Zimmer Biomet (NYSE: ZBH), a global medical technology leader renowned for its comprehensive portfolio aimed at improving mobility and enhancing overall health. This partnership marks a significant turning point for both companies and the field of spinal biologics.
The cornerstone of this partnership is the introduction of a revolutionary synthetic biomaterial for bone growth, slated for a 2024 launch under HippoFi’s subsidiary, PUR Biologics. This development is set to redefine the spinal biologics landscape, promising innovative solutions that could transform the way spinal treatments are approached.
One significant accomplishment of this partnership is the FDA 510(K) clearance HippoFi/PUR received for its ActiveOrb technology, as well as an exclusive worldwide license from Zimmer Biomet for the technology’s use in the spine market. These important achievements demonstrate the companies’ commitment to advancing spinal healthcare.
Ryan Fernan, Head of PUR Biologics, emphasized the significance of this collaboration, stating, “Our collaboration with Zimmer Biomet is a significant stride in our journey to elevate the standards of patient care. We’re excited to bring this innovative technology to the forefront of spinal treatments.”
CJ Wiggins, CEO of HippoFi, echoed this sentiment, emphasizing, “Joining forces with an industry leader like Zimmer Biomet not only amplifies our reach but also reinforces our commitment to delivering breakthrough biologics that transform lives.”
As we look forward to the impact of this partnership, the spotlight is on Zimmer Biomet. Zimmer Biomet (NYSE:ZBH), a globally renowned medical technology leader, boasts a rich legacy of over 90 years. Their mission revolves around enhancing patient mobility and health through groundbreaking products and innovative digital and robotic technologies.
With an impressive financial track record, ZBH reported an EPS of $1.82 for Q2 2023, aligning with analyst predictions. Their robust return on equity (ROE) of 12.36% and a net margin of 7.03% demonstrate their unwavering profitability. This established player in the medical equipment industry continues to evolve, making them a pivotal company to watch.
Orthofix Medical Inc. (NASDAQ:OFIX) headquartered in Lewisville, Texas, is a leading global spine and orthopedics company with a comprehensive portfolio. On January 5, 2023, Orthofix and SeaSpine merged to form a powerhouse in the spine and orthopedics sector. Their combined portfolio includes biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a cutting-edge surgical navigation system. These products are distributed in approximately 68 countries worldwide.
In the second quarter, Orthofix reported a loss of $39.4 million, translating to a per-share loss of $1.07. However, when adjusted for non-recurring costs and merger-related expenses, earnings reached 2 cents per share. Despite these figures, Orthofix has been achieving growth, with 7% year-over-year growth on a pro forma basis and strong performance in the Bone Growth Therapies franchise.
Keith Valentine, President and Chief Executive Officer of Orthofix, expressed optimism about the company’s future. He highlighted their success in managing revenue dis-synergy risks and capitalizing on operating expense synergy opportunities during the merger process. Orthofix also anticipates full-year revenue in the range of $752 million to $758 million.
Additionally, Orthofix recently announced the full commercial launch of the 7D FLASH Navigation System Percutaneous Module 2.0, marking a significant step in serving the Minimally Invasive Surgery (MIS) spine market. This module enhances their capabilities for navigated spinal fusion procedures, offering safety, speed, and efficiency.
Orthofix’s strategic moves and innovations in the spine and orthopedics sectors make it a noteworthy player in this evolving landscape.
Bone Biologics (NASDAQ:BBLG) is a publicly traded company headquartered in Burlington, MA, with a strong focus on the development and marketing of orthobiologic products. At the core of their proprietary platform technology lies NELL-1, a recombinant human protein growth factor essential for normal bone development. The company is dedicated to exploring new applications of the NELL-1 technology to improve bone regeneration and repair, especially in cases where current treatment options yield suboptimal patient outcomes.
In June, Bone Biologics made significant financial moves by announcing the pricing of an underwritten public offering of common stock. This offering included 2,538,071 shares of common stock, priced at $1.97 per share, for a total aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts and offering expenses.
Furthermore, Bone Biologics is gearing up for a pilot clinical trial with clearance to advance into human studies in Australia. The company is poised to make a substantial impact in the $3 billion orthobiologics market, pending the successful completion of pivotal human studies in the United States. Their commitment to innovation and NELL-1 technology positions them as a key player in the field of orthobiologics with the potential to transform bone-related healthcare solutions.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance that are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by HippoFi Inc. to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.